Skip to main content

Advertisement

SpringerLink
Log in

Gastric Cancer: an Evolving Disease

  • Stomach (P Malfertheiner, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Abstract

Purpose of Review

Prevalence of Helicobacter pylori, the primary risk factor for gastric cancer, is declining globally. Paralleling this trend, gastric cancer incidence is also decreasing. Historically, the populations most affected by this neoplasia have been males, Asians, and groups with low socioeconomic status. This review provides an update on recently published literature regarding changes in gastric cancer epidemiology.

Recent Findings

Gastric cancer incidence trends vary by age, sex, race/ethnicity, and tumor anatomical location. Overall incidence appears to be leveling off among young birth cohorts in Western populations, where H. pylori has declined considerably. The changes are more prominent for females and for tumors arising beyond the esophageal-gastric junction.

Summary

The classical incidence pattern of gastric cancer is evolving. While uncertain, several hypotheses may explain the changing burden of disease. The mix of gastric cancer risk factors appears to be shifting, with H. pylori no longer the sole etiological driver. These changes may eliminate the previous predilection of males and lead to increases in overall gastric cancer rates. Analytical studies addressing known and novel factors related to major societal transitions may provide clues to understanding re-emergence of this serious public health problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

EBV:

Epstein-Barr virus

EAPC:

Estimated annual percentage change

IM:

Intestinal metaplasia

NAACCR:

North American Association of Central Cancer Registries

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9. https://doi.org/10.1038/nature13480.

    Article  CAS  Google Scholar 

  2. de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin N Am. 2013;42(2):219–40. https://doi.org/10.1016/j.gtc.2013.01.003.

    Article  Google Scholar 

  3. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49(3):347–53.

    Article  Google Scholar 

  4. Chen Y, Liu L, Wang X, Wang J, Yan Z, Cheng J, et al. Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies. Cancer Epidemiol Biomark Prev : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013;22(8):1395–408. https://doi.org/10.1158/1055-9965.EPI-13-0042.

    Article  Google Scholar 

  5. Shakeri R, Malekzadeh R, Nasrollahzadeh D, Pawlita M, Murphy G, Islami F, et al. Multiplex H. pylori serology and risk of gastric cardia and noncardia adenocarcinomas. Cancer Res. 2015;75(22):4876–83. https://doi.org/10.1158/0008-5472.CAN-15-0556.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. https://doi.org/10.3322/caac.21492.

    Google Scholar 

  7. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283–97.

    Article  CAS  PubMed  Google Scholar 

  8. • Blaser MJ. The theory of disappearing microbiota and the epidemics of chronic diseases. Nat Rev Immunol. 2017;17(8):461–3. https://doi.org/10.1038/nri.2017.77 An update of the disappearing microbiota hypothesis and potential implications for health and disease.

    Article  CAS  PubMed  Google Scholar 

  9. Olefson S, Moss SF. Obesity and related risk factors in gastric cardia adenocarcinoma. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015;18(1):23–32. https://doi.org/10.1007/s10120-014-0425-4.

    Article  Google Scholar 

  10. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52(24):6735–40.

    CAS  PubMed  Google Scholar 

  11. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174. https://doi.org/10.1136/bmj.g3174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. • Luo G, Zhang Y, Guo P, Wang L, Huang Y, Li K. Global patterns and trends in stomach cancer incidence: age, period and birth cohort analysis. International journal of cancer Journal international du cancer. 2017;141(7):1333–44. https://doi.org/10.1002/ijc.30835 Age-period-cohort analysis of international gastric cancer incidence trends overall.

    Article  CAS  PubMed  Google Scholar 

  13. Aragones N, Goicoa T, Pollan M, Militino AF, Perez-Gomez B, Lopez-Abente G, et al. Spatio-temporal trends in gastric cancer mortality in Spain: 1975-2008. Cancer Epidemiol. 2013;37(4):360–9. https://doi.org/10.1016/j.canep.2013.03.009.

    Article  PubMed  Google Scholar 

  14. Eom BW, Jung KW, Won YJ, Yang H, Kim YW. Trends in gastric xancer incidence according to the clinicopathological characteristics in Korea, 1999-2014. Cancer Res Treat. 2018. https://doi.org/10.4143/crt.2017.464.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Song M, Kang D, Yang JJ, Choi JY, Sung H, Lee Y, et al. Age and sex interactions in gastric cancer incidence and mortality trends in Korea. Gastric Cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2015;18(3):580–9. https://doi.org/10.1007/s10120-014-0411-x.

    Article  Google Scholar 

  16. Holster IL, Aarts MJ, Tjwa ET, Lemmens VE, Kuipers EJ. Trend breaks in incidence of non-cardia gastric cancer in the Netherlands. Cancer Epidemiol. 2014;38(1):9–15. https://doi.org/10.1016/j.canep.2013.11.001.

    Article  PubMed  Google Scholar 

  17. Castro C, Peleteiro B, Bento MJ, Lunet N. Trends in gastric and esophageal cancer incidence in northern Portugal (1994-2009) by subsite and histology, and predictions for 2015. Tumori. 2017;103(2):155–63. https://doi.org/10.5301/tj.5000542.

    Article  PubMed  Google Scholar 

  18. •• Anderson WF, Rabkin CS, Turner N, Fraumeni JF, Jr., Rosenberg PS, Camargo MC. The changing face of noncardia gastric cancer incidence among US non-Hispanic whites. Journal of the National Cancer Institute. 2018. doi:https://doi.org/10.1093/jnci/djx262. Age-period-cohort analysis of US gastric cancer incidence trends by anatomic subsite, reporting a new pattern of noncardia gastric cancer.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128(7):765–70. https://doi.org/10.1043/1543-2165(2004)128<765:DTITIA>2.0.CO;2.

    Article  PubMed  Google Scholar 

  20. Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009;18(7):1945–52. https://doi.org/10.1158/1055-9965.EPI-09-0250.

    Article  Google Scholar 

  21. Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. Br J Cancer. 2001;84(3):400–5. https://doi.org/10.1054/bjoc.2000.1602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol. 2010;105(3):493–8. https://doi.org/10.1038/ajg.2009.728.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Zullo A, Hassan C, Romiti A, Giusto M, Guerriero C, Lorenzetti R, et al. Follow-up of intestinal metaplasia in the stomach: when, how and why. World journal of gastrointestinal oncology. 2012;4(3):30–6. https://doi.org/10.4251/wjgo.v4.i3.30.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Liu CY, Wu CY, Lin JT, Lee YC, Yen AM, Chen TH. Multistate and multifactorial progression of gastric cancer: results from community-based mass screening for gastric cancer. J Med Screen. 2006;13(Suppl 1):S2–5.

    PubMed  Google Scholar 

  25. •• Huang KK, Ramnarayanan K, Zhu F, Srivastava S, Xu C, Tan ALK, et al. Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. Cancer Cell. 2018;33(1):137–50 e5. https://doi.org/10.1016/j.ccell.2017.11.018 Comprehensive molecular characterization of subtypes of gastric intestinal metaplasia.

    Article  CAS  PubMed  Google Scholar 

  26. Gonzalez CA, Sanz-Anquela JM, Gisbert JP, Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. International journal of cancer Journal international du cancer. 2013;133(5):1023–32. https://doi.org/10.1002/ijc.28003.

    Article  CAS  PubMed  Google Scholar 

  27. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O’Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44(1):74–94. https://doi.org/10.1055/s-0031-1291491.

    Article  CAS  PubMed  Google Scholar 

  28. Haruma K, Kamada T, Murao T, Yamanaka Y, Ohsawa M, Shiotani A, et al. European guideline for the management of precancerous conditions in the stomach and it’s application to Japan. Nihon Rinsho. 2013;71(8):1479–84.

    PubMed  Google Scholar 

  29. Marques-Silva L, Areia M, Elvas L, Dinis-Ribeiro M. Prevalence of gastric precancerous conditions: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2014;26(4):378–87. https://doi.org/10.1097/MEG.0000000000000065.

    Article  PubMed  Google Scholar 

  30. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20(10):1161–81.

    Article  CAS  PubMed  Google Scholar 

  31. Imai T, Murayama H. Time trend in the prevalence of intestinal metaplasia in Japan. Cancer-Am Cancer Soc. 1983;52(2):353–61.

    CAS  Google Scholar 

  32. Sipponen P, Kimura K. Intestinal metaplasia, atrophic gastritis and stomach cancer: trends over time. Eur J Gastroenterol Hepatol. 1994;6(Suppl 1):S79–83.

    PubMed  Google Scholar 

  33. Yee YK, Wong KW, Hui CK, Chan CK, Chan AO, Lam SK, et al. Prevalence and time trend of intestinal metaplasia in Hong Kong. J Gastroenterol Hepatol. 2009;24(5):896–9. https://doi.org/10.1111/j.1440-1746.2009.05799.x.

    Article  PubMed  Google Scholar 

  34. de Vries AC, Meijer GA, Looman CW, Casparie MK, Hansen BE, van Grieken NC, et al. Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands. Gut. 2007;56(12):1665–70. https://doi.org/10.1136/gut.2007.127167.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Guarner J, Bartlett J, Whistler T, Pierce-Smith D, Owens M, Kreh R, et al. Can pre-neoplastic lesions be detected in gastric biopsies of children with Helicobacter pylori infection? J Pediatr Gastroenterol Nutr. 2003;37(3):309–14.

    Article  PubMed  Google Scholar 

  36. Camacho-Gomez SM, Bernieh A, Saad AG, Tipnis NA. Non-Helicobacter pylori gastric intestinal metaplasia in children: a series of cases and review of the literature. Case Rep Gastrointest Med. 2018;2018:5930415. https://doi.org/10.1155/2018/5930415.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Minalyan A, Benhammou JN, Artashesyan A, Lewis MS, Pisegna JR. Autoimmune atrophic gastritis: current perspectives. Clin Exp Gastroenterol. 2017;10:19–27. https://doi.org/10.2147/CEG.S109123.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Bizzaro N, Antico A. Diagnosis and classification of pernicious anemia. Autoimmun Rev. 2014;13(4–5):565–8. https://doi.org/10.1016/j.autrev.2014.01.042.

    Article  PubMed  Google Scholar 

  39. Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis--pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10(9):529–41. https://doi.org/10.1038/nrgastro.2013.101.

    Article  CAS  PubMed  Google Scholar 

  40. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347(12):911–20. https://doi.org/10.1056/NEJMra020100.

    Article  PubMed  Google Scholar 

  41. • Song H, Held M, Sandin S, Rautelin H, Eliasson M, Soderberg S, et al. Increase in the prevalence of atrophic gastritis among adults age 35 to 44 years old in northern Sweden between 1990 and 2009. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015;13(9):1592–600 e1. https://doi.org/10.1016/j.cgh.2015.04.001 A serosurvey documenting an increasing prevalence of corpus extension atrophic gastritis in young individuals.

    Article  Google Scholar 

  42. Smyk DS, Koutsoumpas AL, Mytilinaiou MG, Rigopoulou EI, Sakkas LI, Bogdanos DP. Helicobacter pylori and autoimmune disease: cause or bystander. World journal of gastroenterology : WJG. 2014;20(3):613–29. https://doi.org/10.3748/wjg.v20.i3.613.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Parsons BN, Ijaz UZ, D’Amore R, Burkitt MD, Eccles R, Lenzi L, et al. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. PLoS Pathog. 2017;13(11):e1006653. https://doi.org/10.1371/journal.ppat.1006653.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009. PLoS One. 2013;8(2):e56060. https://doi.org/10.1371/journal.pone.0056060.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Kuipers EJ. Proton pump inhibitors and Helicobacter pylori gastritis: friends or foes? Basic Clin Pharmacol Toxicol. 2006;99(3):187–94. https://doi.org/10.1111/j.1742-7843.2006.pto_478.x.

    Article  CAS  PubMed  Google Scholar 

  46. Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The gastric and intestinal microbiome: role of proton pump inhibitors. Curr Gastroenterol Rep. 2017;19(8):42. https://doi.org/10.1007/s11894-017-0577-6.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Wennerström ECM, Simonsen J, Camargo MC, Rabkin CS. Acid-suppressing therapies and subsite-specific risk of stomach cancer. Br J Cancer. 2017;116(9):1234–8. https://doi.org/10.1038/bjc.2017.84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137(3):824–33. https://doi.org/10.1053/j.gastro.2009.05.001.

    Article  PubMed  Google Scholar 

  49. Hruby A, Hu FB. The epidemiology of obesity: a big picture. PharmacoEconomics. 2015;33(7):673–89. https://doi.org/10.1007/s40273-014-0243-x.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer. 2009;45(16):2867–73. https://doi.org/10.1016/j.ejca.2009.04.019.

    Article  PubMed  Google Scholar 

  51. Camargo MC, Freedman ND, Hollenbeck AR, Abnet CC, Rabkin CS. Height, weight, and body mass index associations with gastric cancer subsites. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2014;17(3):463–8. https://doi.org/10.1007/s10120-013-0312-4.

    Article  Google Scholar 

  52. Sipponen P, Correa P. Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2002;5(4):213–9. https://doi.org/10.1007/s101200200037.

    Article  Google Scholar 

  53. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012;21(1):20–38. https://doi.org/10.1158/1055-9965.EPI-11-0834.

    Article  CAS  Google Scholar 

  54. Nichols HB, Trentham-Dietz A, Hampton JM, Titus-Ernstoff L, Egan KM, Willett WC, et al. From menarche to menopause: trends among US women born from 1912 to 1969. Am J Epidemiol. 2006;164(10):1003–11. https://doi.org/10.1093/aje/kwj282.

    Article  PubMed  Google Scholar 

  55. Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest. 2009;119(9):2475–87. https://doi.org/10.1172/JCI38605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr., BG 9609/6E338, Rockville, MD, 20852, USA

    Minkyo Song MD, PhD, Charles S. Rabkin MD & M. Constanza Camargo PhD

Authors
  1. Minkyo Song MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles S. Rabkin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Constanza Camargo PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Constanza Camargo PhD.

Ethics declarations

Conflict of Interest

Minkyo Song declares that she has no conflict of interest. Charles S. Rabkin declares that he has no conflict of interest. Constanza Camargo declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Stomach

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Song, M., Rabkin, C.S. & Camargo, M. Gastric Cancer: an Evolving Disease. Curr Treat Options Gastro 16, 561–569 (2018). https://doi.org/10.1007/s11938-018-0203-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-018-0203-1

Keywords

Search

Navigation